Compare BIO-TECHNE Corp (TECH) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Zoom Video Communications, Inc. — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Zoom Video Communications, Inc. trades at $96.83 (market cap $28.14B). The key difference: Zoom Video Communications, Inc. is far larger — about 2.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals.
| TECH | ZM | |
|---|---|---|
Market Cap | $11.34B | $28.14B |
Sector | Health | Technology |
52-Week High | $72.48 | $111.88 |
52-Week Low | $43.31 | $72.72 |
Enterprise Value | $11.36B | $20.95B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Zoom Communications (ZM) trades at $96.44, down 4.83% amid mixed signals. The stock shows bearish technical indicators with support at $95 and resistance at $99, while fundamentals reveal strong profitability with 77.3% gross margins and 65.19% net income margin. Recent Q2 earnings beat expectations with 4.9% revenue growth to $1.28B, but soft Q3 guidance triggered the selloff. Analyst consensus remains cautiously optimistic with a $119.63 price target despite near-term headwinds.
The outlook balances strong cash flow generation against growth deceleration concerns. Investment opportunity lies in ZM's enterprise revenue acceleration (7.8% growth) and attractive valuation (P/E 8.95), while risks include competitive pressure and execution on AI initiatives. The Anthropic IPO catalyst and new board appointment provide potential upside if growth reaccelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
